Embryonal central nervous system tumors such as medulloblastomas and atypical teratoid/rhabdoid tumors are the most common brain cancers in the childhood. These tumors correspond to 10% of all central nervous system cancer cases in children. These are malignant tumors that start in fetal cells in the brain and mainly affect children up to four years old. They tend to contain cells with characteristics similar to those of stem cells, which boosts their tumorigenic potential and capacity to invade tissue while also making them more resistant to cell death. These tumors are caused by genetic or epigenetic aberrations in stem cells and neural progenitors when the nervous system is being formed during embryonic development. The neural stem cells that undergo these alterations later give rise to tumor cells. They form aggressive, fast-growing tumors that may appear shortly after birth, in later childhood or in adolescence. When embryonal central nervous system tumors are conventionally treated with surgery, chemotherapy and/or radiotherapy, morbidity and mortality rates for these patients are still high. Even patients who survive longer than most may suffer from permanent treatment-related sequelae that impair their quality of life, such as problems with development, cognition, locomotion and speech.
In Brazil, scientists affiliated with the Human Genome and Stem Cell Research Center (HUG-CELL) at the University of São Paulo (USP) have identified a molecule capable of reducing the aggressiveness of embryonal central nervous system tumors. The results are published in the journal Molecular Oncology. HUG-CELL is one of the Research, Innovation and Dissemination Centers (RIDCs) supported by São Paulo Research Foundation – FAPESP. Its principal investigator is Mayana Zatz, Professor of Human and Medical Genetics at USP’s Institute of Biosciences. The approach proposed by the group can be classified as a type of microRNA-based therapy. A microRNA is a small RNA molecule that does not encode protein but plays a regulatory role in the genome and the regulation of gene switching. In this study, researchers used a synthetic version of an inhibitor of microRNA-367 (miR-367) with anti-tumor activity. In a previous study, the group tested an approach that used the Zika virus to destroy tumor stem cells. Previous research has already shown that OCT4A, one of the genes that encode pluripotency factors, is overexpressed in aggressive medulloblastomas and that this overexpression is associated with an unfavorable prognosis.
During her master’s research, Kaid detected the expression of miR-367, a gene that promotes stem-like traits in tumor cells, in parallel with overexpression of OCT4A. The researchers then tested a specific synthetic inhibitor of miR-367 containing minor chemical alterations that make it more stable in cells. A patent application has been filed for the invention. After inducing the formation of central nervous system tumors in mice using three different strains of tumor cells, the researchers injected the miR-367 inhibitor into the brain’s right lateral ventricle, a pathway to the cerebrospinal fluid that surrounds the brain and spinal cord. From there, the miR-367 inhibitor was able to access the tumor cells. Tumor size was reduced considerably, and survival improved in all groups of mice. The results confirmed what had previously been observed in cell cultures. In this model, the researchers noted that when the synthetic molecule interacted with miR-367 in tumor cells, it prevented this microRNA from affecting the levels of proteins it normally regulates, such as ITGAV and SUZ12. The latter is known to be involved in silencing pluripotency-related genes in embryonic stem cells. While the role of ITGAV in embryonal central nervous system tumors is not fully understood, ITGAV is known to participate in the renewal of both normal and tumor stem cells.
The researchers believe that in humans, the synthetic molecule alone may be capable of at least containing the development of these tumors and improving survival. Even so, they are testing combinations of the molecule with drugs currently used to treat the tumors. They want to find out whether the approaches could be combined using lower doses of chemotherapy drugs. Before clinical trials can be performed, however, pharmacology and toxicity studies will be necessary, as will pharmacokinetic testing to show how the molecule is metabolized and how long it stays in the organism.
- Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.
Kaid C et al., Okamoto OK. Mol Oncol. 2019 Aug 11.
Rosas Plaza X et al. Cells. 2019 Oct 8; 8(10).
Terbuch A et al. Int J Mol Sci. 2018 Oct 12; 19(10).
Cai W et al. Biomed Pharmacother 2017; 95:120-28.